Funding and Research Opportunities
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
Maryland Tech Council announced today that Nora D. Volkow, M.D., Director of the National Institute on Drug Abuse, National Institutes of Health (NIH) will kick off its new Innovation Speaker Series. Dr. Volkow will discuss the current state of the opioid crisis nationally and locally. Additionally, her presentation will cover what research has shown about this particular addiction, its prevention and treatment, and how science may help end the massive public health crisis. Key industry leaders are expected to attend this inaugural series event, which will take place Wednesday, November 29, 2017 at the Universities at Shady Grove from 7:30-9:30 a.m.
The Johns Hopkins University and Deerfield Management announced today the creation of Bluefield Innovations, a collaboration designed to catalyze the development of early stage therapeutics. Funded by Deerfield, an investment management firm committed to advancing health care, Bluefield Innovations will provide up to $65 million in initial funding over five years to support the commercialization of early stage therapeutic research at Johns Hopkins, with additional funding available to advance research that shows strong commercial potential.
Bioterrorism threats and infectious disease outbreaks are on the rise. Emergent BioSolutions Inc. (EBS) has a stream of revenues from FDA-approved drugs, as well as a full pipeline of drugs under development, to combat these health threats.
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today launched enhancements in its QIAGEN Clinical Insight (QCI) bioinformatics software automating the AMP/ASCO/CAP Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer, advancing precision medicine with the first solution to offer molecular pathologists critical information needed to guide oncologists’ treatment decisions.
FDA approval based on Phase III program demonstrating up to 51% reduction in asthma exacerbations, significant improvement in lung function and a 75% reduction in daily oral steroid use
Date and time: Tuesday, 21 November 5:00PM – 8:00PM EST
Location: MedImmune 1 Medimmune Way Gaithersburg, MD 20878 United States
HBA Mid-Atlantic presents a panel of successful diverse women from the public and private healthcare sectors to share their experiences on harnessing one’s power.
- Primary Competency: 8. Builds relationships and teams
- Secondary Competency: 12. Continues to learn, grow and transform
Scientists for the first time have tried editing a gene inside the body in a bold attempt to permanently change a person’s DNA to cure a disease.
David Narrow said the life of an entrepreneur is fast-paced and at times very stressful, but he has never loved any job more.
His medical technology firm, Sonavex, recently raised $3 million and took up new office space in Canton. The company is currently working on commercializing its product, which uses ultrasound technology to detect potentially harmful, post-surgical blood clots.
Date: Thursday, November 30, 2017
Location: Inova Center for Personalized Health3225 Gallows Road, Fairfax, VA 22031
Technology innovation continues to accelerate at an exponential rate, constantly outpacing the status quo and redefining limitations. Personal healthcare stands to benefit from these newfound opportunities.